Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Aug 23

PMID 34421823

Citations 11

Authors

Shu-Ting Lin

Yi-Zhong Li

Xiao-Qi Sun

Qian-Qian Chen

Shun-Fa Huang

Shu Lin

Si-Qing Cai

Affiliations

Soon will be listed here.

Abstract

Breast cancer and osteoporosis are common diseases that affect the survival and quality of life in postmenopausal women. Women with breast cancer are more likely to develop osteoporosis than women without breast cancer due to certain factors that can affect both diseases simultaneously. For instance, estrogen and the receptor activator of nuclear factor-κB ligand (RANKL) play important roles in the occurrence and development of these two diseases. Moreover, chemotherapy and hormone therapy administered to breast cancer patients also increase the incidence of osteoporosis, and in recent years, neuropeptide Y (NPY) has also been found to impact breast cancer and osteoporosis.Y1 and Y5 receptors are highly expressed in breast cancer, and Y1 and Y2 receptors affect osteogenic response, thus potentially highlighting a potential new direction for treatment strategies. In this paper, the relationship between breast cancer and osteoporosis, the influence of NPY on both diseases, and the recent progress in the research and treatment of these diseases are reviewed.

Citing Articles

Higher Preoperative Serum Neuropeptide Y Concentration May Be Associated with a Better Prognosis After Surgery for Colorectal Cancer.

Budzynski J, Czarnecki D, Ziolkowski M, Szukay B, Mysiak N, Staniewska A Nutrients. 2024; 16(22).

PMID: 39599612 PMC: 11597490. DOI: 10.3390/nu16223825.

Integrative Analysis of Acupuncture Targets and Immune Genes in Diabetes, Diabetic Peripheral Neuropathy, and Adjunct Therapy of Cancer.

Zhang Q, Luo W, Li J, Zhang Q, Guo Q, Chen J J Multidiscip Healthc. 2024; 17:4939-4962.

PMID: 39492981 PMC: 11529286. DOI: 10.2147/JMDH.S483940.

Heterobivalent Dual-Target Peptide for Integrin-αβ and Neuropeptide Y Receptors on Breast Tumor.

Ferreira A, Real C, Malafaia O Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458969 PMC: 11510292. DOI: 10.3390/ph17101328.

Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer.

Mejia-Barradas C, Amador-Martinez A, Lara-Padilla E, Cardenas-Rodriguez N, Ignacio-Mejia I, Martinez-Lopez V Cancers (Basel). 2024; 16(16).

PMID: 39199661 PMC: 11352457. DOI: 10.3390/cancers16162891.

Investigating mechanical and inflammatory pathological mechanisms in osteoarthritis using MSC-derived osteocyte-like cells in 3D.

Gilbert S, Jones R, Egan B, Bonnet C, Evans S, Mason D Front Endocrinol (Lausanne). 2024; 15:1359052.

PMID: 39157681 PMC: 11328832. DOI: 10.3389/fendo.2024.1359052.

References

Li J, Shen Z, Ma X, Ren W, Xiang L, Gong A . Neuropeptide Y Y1 receptors mediate [corrected] targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy. ACS Appl Mater Interfaces. 2015; 7(9):5574-82. DOI: 10.1021/acsami.5b00270. View

Wu J, Jiang N, Yu B . Mechanisms of action of neuropeptide Y on stem cells and its potential applications in orthopaedic disorders. World J Stem Cells. 2020; 12(9):986-1000. PMC: 7524693. DOI: 10.4252/wjsc.v12.i9.986. View

Vall-Sagarra A, Litau S, Decristoforo C, Wangler B, Schirrmacher R, Fricker G . Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors-An Improvement for Breast Cancer Imaging?. Pharmaceuticals (Basel). 2018; 11(3). PMC: 6161111. DOI: 10.3390/ph11030065. View

Chen W, Liu Y, Liu W, Zhou Y, He H, Lin S . Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect. Front Immunol. 2020; 11:580378. PMC: 7573154. DOI: 10.3389/fimmu.2020.580378. View

Baldock P, Sainsbury A, Couzens M, Enriquez R, Thomas G, M Gardiner E . Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002; 109(7):915-21. PMC: 150931. DOI: 10.1172/JCI14588. View

. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015; 386(10001):1353-1361. DOI: 10.1016/S0140-6736(15)60908-4. View

Allison S, Herzog H . NPY and bone. EXS. 2005; (95):171-82. DOI: 10.1007/3-7643-7417-9_13. View

Leslie W, Brennan-Olsen S, Morin S, Lix L . Fracture prediction from repeat BMD measurements in clinical practice. Osteoporos Int. 2015; 27(1):203-10. DOI: 10.1007/s00198-015-3259-y. View

Xu Y, Liu X, Li H, Liu H, Pan Z, Chen G . Brain neural effects of the 'tonifying kidney and benefiting marrow' method in the treatment of osteoporosis. J Tradit Chin Med. 2020; 39(6):902-909. View

10.

Kufka R, Rennert R, Kaluderovic G, Weber L, Richter W, Wessjohann L . Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein J Org Chem. 2019; 15:96-105. PMC: 6334802. DOI: 10.3762/bjoc.15.11. View

11.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

12.

Medeiros P, Jackson D . Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis. Peptides. 2013; 48:106-13. DOI: 10.1016/j.peptides.2013.07.029. View

13.

Baldock P, Allison S, Lundberg P, Lee N, Slack K, Lin E . Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem. 2007; 282(26):19092-102. DOI: 10.1074/jbc.M700644200. View

14.

Memminger M, Keller M, Lopuch M, Pop N, Bernhardt G, von Angerer E . The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. PLoS One. 2012; 7(12):e51032. PMC: 3517602. DOI: 10.1371/journal.pone.0051032. View

15.

Ramaswamy B, Shapiro C . Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003; 30(6):763-75. DOI: 10.1053/j.seminoncol.2003.08.028. View

16.

Milat F, Vincent A . Management of bone disease in women after breast cancer. Climacteric. 2015; 18 Suppl 2:47-55. DOI: 10.3109/13697137.2015.1100383. View

17.

Ruscica M, Dozio E, Motta M, Magni P . Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides. 2007; 28(2):426-34. DOI: 10.1016/j.peptides.2006.08.045. View

18.

Hamood R, Hamood H, Merhasin I, Keinan-Boker L . Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. Osteoporos Int. 2018; 30(1):187-200. DOI: 10.1007/s00198-018-4758-4. View

19.

Amlal H, Faroqui S, Balasubramaniam A, Sheriff S . Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res. 2006; 66(7):3706-14. DOI: 10.1158/0008-5472.CAN-05-2744. View

20.

Khosla S, Hofbauer L . Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11):898-907. PMC: 5798872. DOI: 10.1016/S2213-8587(17)30188-2. View